Anti-Human PD-L1 Nanobody for Immuno-PET Imaging: Validation of a Conjugation Strategy for Clinical Translation

Immune checkpoints, such as programmed death-ligand 1 (PD-L1), limit T-cell function and tumor cells use this ligand to escape the anti-tumor immune response. Treatments with monoclonal antibodies blocking these checkpoints have shown long-lasting responses, but only in a subset of patients. This st...

Descripción completa

Detalles Bibliográficos
Autores principales: Bridoux, Jessica, Broos, Katrijn, Lecocq, Quentin, Debie, Pieterjan, Martin, Charlotte, Ballet, Steven, Raes, Geert, Neyt, Sara, Vanhove, Christian, Breckpot, Karine, Devoogdt, Nick, Caveliers, Vicky, Keyaerts, Marleen, Xavier, Catarina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599876/
https://www.ncbi.nlm.nih.gov/pubmed/33003481
http://dx.doi.org/10.3390/biom10101388

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599876/
https://www.ncbi.nlm.nih.gov/pubmed/33003481
http://dx.doi.org/10.3390/biom10101388

Ejemplares similares